ArticleOncotarget2018

MGMT inhibition in ER positive breast cancer leads to CDC2, TOP2A, AURKB, CDC20, KIF20A, Cyclin A2, Cyclin B2, Cyclin D1, ERα and Survivin inhibition and enhances response to temozolomide.

George C Bobustuc et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.